Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

NCT04982068 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: 202-CoV low adjuvant dose
BIOLOGICAL: 202-CoV low antigen dose
BIOLOGICAL: 202-CoV standard dose
OTHER: Placebo

Sponsor

Shanghai Zerun Biotechnology Co.,Ltd

Collaborators

[object Object]